Welcome to our dedicated page for Biocorrx SEC filings (Ticker: BICX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Biocorrx's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Biocorrx's regulatory disclosures and financial reporting.
BioCorRx Inc. reported unaudited results for the three months ended March 31, 2026, showing a small increase in revenue but continued losses and tight liquidity. Net sales rose to $214,539 from $134,899, driven mainly by supply and distribution sales of Lucemyra, its opioid withdrawal treatment. The company also recognized $362,597 of grant income supporting development of its sustained-release naltrexone programs.
Operating expenses climbed to $1,170,539, including higher research and development spending of $352,333, resulting in a loss from operations of $956,000. Net loss attributable to BioCorRx was $831,227, or $(0.03) per basic and diluted share, slightly better than the prior-year loss of $841,407 and $(0.06) per share, helped by lower non-related-party interest expense.
Liquidity remains strained. Cash totaled only $211,911 with a working capital deficit of $7,506,752 and total liabilities of $13,948,134 against assets of $2,324,865. Management disclosed that these conditions raise “substantial doubt” about the company’s ability to continue as a going concern. To bridge its funding gap, BioCorRx relied on a $500,000 common stock subscription from its president, conversions and amendments of several promissory notes, and $85,904 of new related-party advances during the quarter.
BioCorRx Inc. entered into a stock exchange agreement with three insider shareholders, issuing 2,263,371 shares of its common stock in exchange for 1,215 shares of BioCorRx Pharmaceuticals, Inc., its majority‑owned subsidiary, representing about 12.15% of the subsidiary’s outstanding common stock.
The exchange aligns with a Plan of Reorganization adopted on February 25, 2026, under which BioCorRx intends to acquire control of the subsidiary within the meaning of Sections 368(a)(1)(B) and 368(c) of the Internal Revenue Code. The transaction closed on March 27, 2026 and was approved by the board under the company’s related party transaction policy.
The new BioCorRx shares were issued as unregistered, “restricted securities” in a private transaction relying on Section 4(a)(2) of the Securities Act, involved no cash consideration, and provide the participating shareholders with specified registration rights for their newly issued shares.
BioCorRx Inc. reports another year of losses in 2025 while advancing its addiction-treatment pipeline and adding a commercial product. The company posted a loss from operations of $3,508,763 and a net loss to common shareholders of $3,440,146, and its auditors expressed substantial doubt about its ability to continue as a going concern.
The business centers on the Beat Addiction Recovery program, the UnCraveRx weight-loss program, and lead drug candidate BICX104, a long-acting naltrexone implant for opioid and alcohol use disorders and methamphetamine use disorder. Grant income rose to $2,435,848 in 2025, supported by a multi‑year NIDA award totaling $11,029,977 to fund BICX104 research.
In March 2025, a subsidiary acquired rights to Lucemyra, an FDA‑approved opioid‑withdrawal medication, with a $400,000 upfront purchase price paid from a share of future Lucemyra sales plus 500,000 shares and 500,000 warrants. The company also raised equity at $0.35 per share, issuing over 5 million new shares alongside warrants, contributing to dilution. As of March 27, 2026, it had 26,402,874 common shares outstanding and continues to depend on grants and external financing to fund operations.
BioCorRx (BICX) filed its Q3 2025 10‑Q, highlighting its first meaningful product revenue following the Lucemyra asset purchase. Supply and distribution sales reached $635,224 for the quarter and $946,572 year‑to‑date, driving total net sales of $948,362 for the nine months. The company recorded a Q3 net loss attributable to BioCorRx of $1,917,873 and a year‑to‑date loss of $3,992,701, reflecting higher operating expenses as the business scales.
Cash was $287,688 with a working capital deficit of $13,575,951, and management disclosed substantial doubt about the company’s ability to continue as a going concern. Total assets rose to $7,533,473, including intangible assets of $3,011,833 and goodwill of $2,840,400 tied to the US WorldMeds Lucemyra acquisition, while total liabilities were $20,297,768. The company recognized Q3 grant income of $867,130 under NIDA awards and reported a grant receivable of $761,515 and deferred grant revenue of $56,590. Operating expenses increased to $2,580,811 in Q3, including research and development of $1,004,660 and SG&A of $1,145,353, leading to a Q3 operating loss of $1,945,587.